Literature DB >> 8752192

Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy.

S Betocchi1, F Piscione, A Losi M, L Pace, M Boccalatte, P Perrone-Filardi, C Briguori, F Manganelli, Q Ciampi, M Salvatore, M Chiariello.   

Abstract

Hypertrophic cardiomyopathy (HC) is characterized by impaired diastolic function, and left ventricular (LV) outflow tract obstruction in about one-fourth of patients. Verapamil improves diastolic properties, but may have dangerous adverse effects. This study investigates the effects of diltiazem on hemodynamics and LV function in 16 patients with HC who were studied with cardiac catheterization and simultaneous radionuclide angiography. Studies were performed during atrial pacing (15 beats above spontaneous rhythm) at baseline and during intravenous diltiazem administration (0.25 mg x kg(-1) over 2 minutes, and 0.014 mg x kg(-1) x min(-1). Diltiazem induced a systemic vasodilation (cardiac index: 3.4 +/- 1.0 to 4.0 +/- 1.0 L x min(-1) x m(-2), p = 0.003; aortic systolic pressure: 116 +/- 16 to 107 +/- 19 mm Hg, p = 0.007; systemic resistance index: 676 +/- 235 to 532 +/- 193 dynes x s x cm(-5) x m(-2), p = 0.006), not associated with changes in the LV outflow tract gradient. The end-systolic pressure/volume ratio decreased (30 +/- 42 to 21 +/- 29 mm Hg x ml(-1) x m(-2); p = 0.044). Pulmonary artery wedge pressure (11 +/- 5 to 15 +/- 6 mm Hg, p = 0.006), and peak filling rate increased (4.1 +/- 1.3 to 6.0 +/- 2.4 stroke counts x s(-1), p = 0.004). The time constant of isovolumetric relaxation tau decreased (74 +/- 40 to 59 +/- 38 ms, p = 0.045). The constant of LV chamber stiffness did not change. Thus, active diastolic function is improved by the acute administration of diltiazem by both direct action and changes in hemodynamics and loading conditions. LV outflow tract gradient does not increase despite systemic vasodilation. In some patients, however, a marked increase in obstruction and a potentially harmful elevation in pulmonary artery wedge pressure do occur. Passive diastolic function is not affected.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8752192     DOI: 10.1016/s0002-9149(96)00336-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Assessment of left ventricular diastolic function with electrocardiography-gated myocardial perfusion SPECT: comparison with multigated equilibrium radionuclide angiography.

Authors:  S Kumita; K Cho; H Nakajo; M Toba; M Uwamori; S Mizumura; T Kumazaki; J Sano; S Sakai; K Munakata
Journal:  J Nucl Cardiol       Date:  2001 Sep-Oct       Impact factor: 5.952

Review 2.  Pacing for drug-refractory or drug-intolerant hypertrophic cardiomyopathy.

Authors:  Mohammed Qintar; Abdulrahman Morad; Hazem Alhawasli; Khaled Shorbaji; Belal Firwana; Adib Essali; Waleed Kadro
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Weaning failure from mechanical ventilation due to hypertrophic obstructive cardiomyopathy.

Authors:  Chris Adamopoulos; Matthew Tsagourias; Kostoula Arvaniti; Fotini Veroniki; Dimitrios Matamis
Journal:  Intensive Care Med       Date:  2005-04-06       Impact factor: 17.440

Review 4.  Pharmacological Management of Hypertrophic Cardiomyopathy: From Bench to Bedside.

Authors:  Chiara Palandri; Lorenzo Santini; Alessia Argirò; Francesca Margara; Ruben Doste; Alfonso Bueno-Orovio; Iacopo Olivotto; Raffaele Coppini
Journal:  Drugs       Date:  2022-06-13       Impact factor: 11.431

Review 5.  Cardiomyopathies: Evolution of pathogenesis concepts and potential for new therapies.

Authors:  Hamayak Sisakian
Journal:  World J Cardiol       Date:  2014-06-26

6.  Aortic Stiffness in Youth with Hypertrophic Cardiomyopathy Genotype.

Authors:  Justin P Zachariah; Philip K Johnson; Steven D Colan
Journal:  Pediatr Cardiol       Date:  2016-04-04       Impact factor: 1.655

7.  Effect of hypertrophy on left ventricular diastolic function in patients with hypertrophic cardiomyopathy.

Authors:  Quirino Ciampi; Sandro Betocchi; Maria Angela Losi; Raffaella Lombardi; Bruno Villari; Massimo Chiariello
Journal:  Heart Int       Date:  2006-09-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.